Results 101 to 110 of about 119,519 (336)

Driving chronicity in rheumatoid arthritis: perpetuating role of myeloid cells [PDF]

, 2018
Acute inflammation is a complex and tightly regulated homeostatic process that includes leukocyte migration from the vasculature into tissues to eliminate the pathogen/injury, followed by a pro-resolving response promoting tissue repair.
Achuthan, Alivernini, Alivernini, Alvaro-Gracia, Anderson, Asquith, Bamboat, Behrens, Bell, Ben Nasr, Benham, Black, Bluml, Brentano, Burmester, Burmester, Burmester, Catrina, Cauli, Cheung, Chu, Chu, Couzin-Frankel, Cramer, Cross, den Berg, den Brand, Dillon, Donlin, Ehrenstein, Elmesmari, Ferraccioli, Field, Firestein, Frank-Bertoncelj, Gao, Ginhoux, Greven, Guiducci, Guo, Hambleton, Hamilton, Haschka, Herenius, Hogg, Hurst, Iliev, James, Jongbloed, Kaplanski, Kokkonen, Kollias, Konig, Kriegler, Kurowska-Stolarska, Kurowska-Stolarska, Kurowska-Stolarska, Lemke, Malmstrom, Mann, McInnes, McInnes, McInnes, McLoughlin, Midwood, Miller, Misharin, Misso, Moret, Moret, Morton, Murata, Na, Nagy, Nassar, Ng, O'Connell, O'Connell, O'Keeffe, Ohshima, Okada, Paolino, Park, Rajasekhar, Ramwadhdoebe, Rauber, Reynolds, Roberts, Rothlin, Rupaimoole, Rycke, Sacre, Schett, Singh, Smith, Smith, Smolen, Sokolove, Stanczyk, Steidl, Takeuchi, Tannahill, Thai, Tsoumakidou, Udalova, Vandenabeele, Villani, Watts, Weinblatt, Weiss, Williamson, Wolf, Xiong, Yeo, Yu, Zou   +115 more
core   +1 more source

OCTN2 Activates a Non‐Canonical Carnitine Metabolic Pathway to Promote MASH‐HCC Progression and Immunotherapy Resistance

Advanced Science, EarlyView.
In non‐MASH‐HCC, L‐carnitine promotes tumor progression primarily through its classical role in enhancing fatty acid oxidation (FAO). However, in MASH‐HCC, where FAO is markedly suppressed, L‐carnitine shifts from this canonical function to serve instead as an intracellular acetyl group buffer.
Chuqi Xia, Xiao Zhang, Jinze Li, Ning Xu, Sheng Hu, Qiyu Lu, Yuxuan Li, Taifu Xiao, Xu Li, Xue Wang, Kequan Xu, Daoming Liang   +11 more
wiley   +1 more source

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Journal of Hematology & Oncology, 2017
Background The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis.
Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W. N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Mark Jones, Deanna Kornacki, Kang Sun, Hagop Kantarjian, for the COMFORT-I investigators   +21 more
doaj   +1 more source

Signalling, cell cycle and pluripotency in embryonic stem cells [PDF]

, 2002
International ...
Burdon, Tom, Savatier, Pierre, Smith, Austin   +2 more
core   +1 more source

Cell‐Free DNA‐Based Theranostics for Inflammatory Disorders

Advanced Science, EarlyView.
Summary on the dual potential of cfDNA as biomarkers and therapeutic targets for inflammatory disorders. Figure was created with BioRender.com. ABSTRACT Inflammatory disorders are characterized by immune‐mediated inflammatory cascades that can affect multiple organs.
Jiatong Li, Yumei Wang, Xiaoxi Fan, Miao Xu, Jiawen Li, Wenfei Tan, Jianxiang Zhang, Heran Li   +7 more
wiley   +1 more source

Loss of signal transducer and activator of transcription 1 is associated with prostate cancer recurrence [PDF]

, 2015
STAT1 loss has previously been implicated in cell line studies to modify prostate cancer cell growth and survival, however the clinical significance of this has not previously been established.
Edwards, Joanne, Hatziieremia, Sophia, McCall, Pamela, Mohammed, Zahra, Roseweir, Antonia K., Underwood, Mark A., Willder, Jennifer M.   +6 more
core   +1 more source

Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study [PDF]

, 2023
Pablo A. Jimenez, Howard Sofen, Robert Bissonnette, Mark Lee, Joseph F. Fowler, David J. Zammit, Yusong Chen, Niranjan Rao, Louis Denis, Sandeep Kumar Gupta   +9 more
openalex   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

DENDRITIC CELL DIFFERENTIATION BLOCKED BY PRIMARY EFFUSION LYMPHOMA-RELEASED FACTORS IS PARTIALLY RESTORED BY INHIBITION OF P38 MAPK [PDF]

, 2010
To better understand the molecular mechanisms underlying the dendritic cell (DC) defects in cancer, we analyzed which signaling pathway is implicated in the abnormal monocyte differentiation into DC determined by the presence of Primary effusion lymphoma
CIRONE, Mara, DI RENZO, Livia Maria, FAGGIONI, Alberto, FRATI, Luigi, G. Borgia, G. Lucania, TRIVEDI, PANKAJ   +6 more
core   +2 more sources

Efficacy and safety of Janus kinase inhibitors for Ulcerative colitis：A Systematic Review and Meta-Analysis [PDF]

, 2021
Tian Zhao, shi qin, Lu Fu
openalex   +1 more source